EGI
AUPH icon

EAM Global Investors’s Aurinia Pharmaceuticals AUPH Stock Holding History

EAM Global Investors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-157,128
Closed -$2.28M – 122
2020
Q1 		$2.28M Sell
157,128
-2,856
-2% -$50.4K 1.33% 16
2019
Q4 		$3.24M Buy
+159,984
New +$1.47M 1.3% 12

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

EAM Global Investors's AUPH Position: Q2 2020 in Review

EAM Global Investors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2020, closing a stake of 157,128 shares — an estimated $2.28M sold.

EAM Global Investors first reported a position in AUPH in Q4 2019 and held it in 2 quarters. The position peaked at $3.24M in Q4 2019. 132 funds tracked by Wall St. Rank hold AUPH as of Q2 2020.

  • EAM Global Investors reported no remaining Aurinia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • EAM Global Investors sold 157,128 Aurinia Pharmaceuticals shares in Q2 2020, an estimated $2.28M.
  • EAM Global Investors first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • EAM Global Investors's Aurinia Pharmaceuticals position peaked at $3.24M in Q4 2019.
  • 132 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2020.

Based on EAM Global Investors's 13F filing for Q2 2020, filed 13 Aug 2020.